Skip to search formSkip to main contentSkip to account menu

CAE Regimen

Known as: ACE Regimen, Cytoxan-Adriamycin-Etoposide Regimen 
A regimen consisting of cyclophosphamide, doxorubicin and etoposide used for the treatment of extensive-stage small cell lung cancer.
National Institutes of Health

Related topics

Related topics

4 relations
CyclophosphamideDoxorubicinEtoposideSmall cell carcinoma of lung

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
2000
2000
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors
Patients with nhl and two or three factors of the international prognostic index (ipi) have a poor prognosis. we performed a… 
1986
1986
Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)